Skip to main content

Advertisement

SpringerLink
Log in

Progress in moyamoya disease

  • Review
  • Published:
Neurosurgical Review Aims and scope Submit manuscript

Abstract

Moyamoya disease is characterized by progressive stenosis or occlusion of the intracranial portion of the internal carotid artery and their proximal branches, resulting in ischemic or hemorrhagic stroke with high rate of disability and even death. So far, available treatment strategies are quite limited, and novel intervention method is being explored. This review encapsulates current advances of moyamoya disease on the aspects of epidemiology, etiology, clinical features, imaging diagnosis and treatment. In addition, we also bring forward our conjecture, which needs to be testified by future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Takeuchi K, Shimizu K (1957) Hypoplasia of the bilateral internal carotid arteries. Brain Nerve 9:37–43

    Google Scholar 

  2. Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. N Engl J Med 360:1226–1237

    Article  CAS  PubMed  Google Scholar 

  3. Matsushima T, Inoue T, Natori Y, Fujii K, Fukui M, Hasuo K, Kuwabara Y (1994) Children with unilateral occlusion or stenosis of the ICA associated with surrounding moyamoya vessels--"unilateral" moyamoya disease. Acta Neurochir 131(3–4):196–202

    Article  CAS  PubMed  Google Scholar 

  4. Goto Y, Yonekawa Y (1992) Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo) 32(12):883–886

    Article  CAS  Google Scholar 

  5. Kuroda S, Houkin K (2008) Moyamojyya disease: current concepts and future perspectives. Lancet Neurol 7(11):1056–1066

    Article  PubMed  Google Scholar 

  6. Ma Y, Zhao M, Zhang Q, Liu X, Zhang D, Wang S, Zhang Y, Li M, Zhao J (2017) Risk factors for epilepsy recurrence after revascularization in pediatric patients with moyamoya disease. J Stroke Cerebrovasc Dis 27(3):740–746

    Article  PubMed  Google Scholar 

  7. Porras JL, Yang W, Xu R et al (2017) Effectiveness of ipsilateral stroke prevention between conservative management and indirect revascularization for moyamoya disease (MMD) in a North American cohort. World Neurosurg 110:e928–e936

    Article  PubMed  Google Scholar 

  8. Qiao PG, Han C, Zuo ZW, Wang YT, Pfeuffer J, Duan L, Qian T, Li GJ (2017) Clinical assessment of cerebral hemodynamics in Moyamoya disease via multiple inversion time arterial spin labeling and dynamic susceptibility contrast-magnetic resonance imaging: a comparative study. J Neuroradiol 44(4):273–280

    Article  PubMed  Google Scholar 

  9. Su P, Mao D, Liu P, Li Y, Pinho MC, Welch BG, Lu H (2017) Multiparametric estimation of brain hemodynamics with MR fingerprinting ASL. Magn Reson Med 78(5):1812–1823

    Article  PubMed  Google Scholar 

  10. Duan L, Wei L, Tian Y, Zhang Z, Hu P, Wei Q, Liu S, Zhang J, Wang Y, Li D, Yang W, Zong R, Xian P, Han C, Bao X, Zhao F, Feng J, Liu W, Cao W, Zhou G, Zhu C, Yu F, Yang W, Meng Y, Wang J, Chen X, Wang Y, Shen B, Zhao B, Wan J, Zhang F, Zhao G, Xu A, Zhang X, Liu J, Zuo X, Wang K (2018) Novel susceptibility loci for moyamoya disease revealed by a genome-wide association study. Stroke 49(1):11–18

    Article  CAS  PubMed  Google Scholar 

  11. Wakai K, Tamakoshi A, Ikezaki K et al (2008) Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke 39(1):42–47

    Article  PubMed  Google Scholar 

  12. Baba T, Houkin K, Kuroda S (2008) Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 79(8):900–904

    Article  CAS  PubMed  Google Scholar 

  13. Hoshino H, Izawa Y, Suzuki N (2012) Epidemiological features of moyamoya disease in Japan. Neurol Med Chir (Tokyo) 52(5):295–298

  14. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, Kojima M, Lin Y, Ohno Y (1997) Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 99(Suppl 2):S1–S5

    Article  PubMed  Google Scholar 

  15. Ikezaki K, Han DH, Kawano T, Inamura T, Fukui M (1997) Epidemiological survey of moyamoya disease in Korea. Clin Neurol Neurosurg 99(Suppl 2):S6–S10

  16. Ikezaki K, Han DH, Kawano T et al (1997) A clinical comparison of definite moyamoya disease between South Korea and Japan. Stroke 28(12):2513–2517

    Article  CAS  PubMed  Google Scholar 

  17. Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, Ahn HS (2014) Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study. Stroke 45(4):1090–1095

    Article  PubMed  Google Scholar 

  18. Kim T, Lee H, Bang JS, Kwon OK, Hwang G, Oh CW (2015) Epidemiology of moyamoya disease in Korea: based on National Health Insurance Service data. J Korean Neurosurg Soc 57(6):390–395

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Miao W, Zhao PL, Zhang YS, Liu HY, Chang Y, Ma J, Huang QJ, Lou ZX (2010) Epidemiological and clinical features of moyamoya disease in Nanjing, China. Clin Neurol Neurosurg 112(3):199–203

    Article  PubMed  Google Scholar 

  20. Duan L, Bao XY, Yang WZ, Shi WC, Li DS, Zhang ZS, Zong R, Han C, Zhao F, Feng J (2012) Moyamoya disease in China: its clinical features and outcomes. Stroke 43(1):56–60

    Article  PubMed  Google Scholar 

  21. Hung CC, Tu YK, Su CF, Lin LS, Shih CJ (1997) Epidemiological study of moyamoya disease in Taiwan. Clin Neurol Neurosurg 99(Suppl 2):S23–S25

    Article  PubMed  Google Scholar 

  22. Chen PC, Yang SH, Chien KL, Tsai IJ, Kuo MF (2014) Epidemiology of moyamoya disease in Taiwan: a nationwide population-based study. Stroke 45(5):1258–1263

    Article  PubMed  Google Scholar 

  23. Chiu D, Shedden P, Bratina P, Grotta JC (1998) Clinical features of moyamoya disease in the United States. Stroke 29(7):1347–1351

    Article  CAS  PubMed  Google Scholar 

  24. Kainth D, Chaudhry SA, Kainth H, Suri FK, Qureshi AI (2013) Epidemiological and clinical features of moyamoya disease in the USA. Neuroepidemiology 40(4):282–287

    Article  PubMed  Google Scholar 

  25. Wang Y, Zhao X, Liu L, Soo YOY, Pu Y, Pan Y, Wang Y, Zou X, Leung TWH, Cai Y, Bai Q, Wu Y, Wang C, Pan X, Luo B, Wong KSL, for the CICAS Study Group, Additional members of the CICAS study group are as follows:, Zhang X, Sun X, Yu L, Guo M, Ma Q, Xiao B, Zhang L, Zhang Z, Xu A, Li J, Lin J, Xing C, Xu Y, Zheng R, Han Z, Yuan X, Cui W, Zou Y, Yan H (2014) Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) study. Stroke 45(3):663–669

  26. Rafat N, Beck GC, Peña-Tapia PG et al (2009) Increased levels of circulating endothelial progenitor cells in patients with moyamoya disease. Stroke 40(2):432–438

    Article  CAS  PubMed  Google Scholar 

  27. Kim JH, Jung JH, Phi JH, Kang HS, Kim JE, Chae JH, Kim SJ, Kim YH, Kim YY, Cho BK, Wang KC, Kim SK (2010) Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res 88(3):510–518

    CAS  PubMed  Google Scholar 

  28. Choi JW, Son SM, Mook-Jung I et al (2017) Mitochondrial abnormalities related to the dysfunction of circulating endothelial colony-forming cells in moyamoya disease. J Neurosurg 8:1–9

    Google Scholar 

  29. Yoshihara T, Taguchi A, Matsuyama T, Shimizu Y, Kikuchi-Taura A, Soma T, Stern DM, Yoshikawa H, Kasahara Y, Moriwaki H, Nagatsuka K, Naritomi H (2008) Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab 28(6):1086–1089

    Article  CAS  PubMed  Google Scholar 

  30. Jung KH, Chu K, Lee ST, Park HK, Kim DH, Kim JH, Bahn JJ, Song EC, Kim M, Lee SK, Roh JK (2008) Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab 28(11):1795–1803

    Article  CAS  PubMed  Google Scholar 

  31. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242–248

    Article  CAS  PubMed  Google Scholar 

  32. Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, Cho BK, Kim SK (2010) Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry 81(6):673–678

    Article  PubMed  Google Scholar 

  33. Sakamoto S, Kiura Y, Yamasaki F, Shibukawa M, Ohba S, Shrestha P, Sugiyama K, Kurisu K (2008) Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg Rev 31(1):77–81

    Article  PubMed  Google Scholar 

  34. van Setten GB (1995) Basic fibroblast growth factor in human saliva: detection and physiological implications. Laryngoscope 105(6):610–612

    Article  PubMed  Google Scholar 

  35. Takahashi A, Sawamura Y, Houkin K, Kamiyama H, Abe H (1993) The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett 160(2):214–216

    Article  CAS  PubMed  Google Scholar 

  36. Yoshimoto T, Houkin K, Takahashi A, Abe H (1996) Angiogenic factors in moyamoya disease. Stroke 27(12):2160–2165

    Article  CAS  PubMed  Google Scholar 

  37. Morishita R, Sakaki M, Yamamoto K, Iguchi S, Aoki M, Yamasaki K, Matsumoto K, Nakamura T, Lawn R, Ogihara T, Kaneda Y (2002) Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation 105(12):1491–1496

    Article  CAS  PubMed  Google Scholar 

  38. Nanba R, Kuroda S, Ishikawa T, Houkin K, Iwasaki Y (2004) Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 35(12):2837–2842

    Article  CAS  PubMed  Google Scholar 

  39. Yamamoto M, Aoyagi M, Tajima S, Wachi H, Fukai N, Matsushima Y, Yamamoto K (1997) Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 28(9):1733–1738

    Article  CAS  PubMed  Google Scholar 

  40. Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, Matsuura N, Ishizaki R, Kikuchi H, Hashimoto N (1998) Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 89(4):623–629

    Article  CAS  PubMed  Google Scholar 

  41. Bower RS, Mallory GW, Nwojo M, Kudva YC, Flemming KD, Meyer FB (2013) Moyamoya disease in a primarily white, midwestern US population: increased prevalence of autoimmune disease. Stroke 44(7):1997–1999

    Article  PubMed  Google Scholar 

  42. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue T, Ikezaki K, Matsushima T, Fukui M (2000) Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31(4):930–935

    Article  CAS  PubMed  Google Scholar 

  43. Inoue TK, Ikezaki K, Sasazuki T, Ono T, Kamikawaji N, Matsushima T, Fukui M (1997) DNA typing of HLA in the patients with moyamoya disease. Jpn J Hum Genet 42(4):507–515

    Article  CAS  PubMed  Google Scholar 

  44. Kraemer M, Horn PA, Roder C, Khan N, Diehl RR, Berlit P, Heinemann FM (2012) Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic moyamoya angiopathy. Acta Neurochir 154(3):445–454

    Article  PubMed  Google Scholar 

  45. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, Kanno J, Niihori T, Ono M, Ishii N, Owada Y, Fujimura M, Mashimo Y, Suzuki Y, Hata A, Tsuchiya S, Tominaga T, Matsubara Y, Kure S (2011) A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet 56(1):34–40

    Article  CAS  PubMed  Google Scholar 

  46. Liao X, Deng J, Dai W, Zhang T, Yan J (2017) Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review. Environ Health Prev Med 22(1):75

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Park YS, An HJ, Kim JO et al (2017) The role of RNF213 4810G>A and 4950G>A variants in patients with moyamoya disease in Korea. Int J Mol Sci 18(11):E2477

    Article  PubMed  CAS  Google Scholar 

  48. Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, Song D, Zhang J, Guan M, Gu Y (2012) Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 7(10):e48179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Dai D, Lu Q, Huang Q, Yang P, Hong B, Xu Y, Zhao W, Liu J, Li Q (2014) Serum miRNA signature in moyamoya disease. PLoS One 9(8):e102382

    Article  PubMed  PubMed Central  Google Scholar 

  50. Gao F, Yu L, Zhang D, Zhang Y, Wang R, Zhao J (2016) Long noncoding RNAs and their regulatory network: potential therapeutic targets for adult moyamoya disease. World Neurosurg 93:111–119

    Article  PubMed  Google Scholar 

  51. Zhao M, Gao F, Zhang D, Wang S, Zhang Y, Wang R, Zhao J (2017) Altered expression of circular RNAs in moyamoya disease. J Neurol Sci 381:25–31

    Article  CAS  PubMed  Google Scholar 

  52. Masuda J, Ogata J, Yutani C (1993) Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 24(12):1960–1967

    Article  CAS  PubMed  Google Scholar 

  53. Lin R, Xie Z, Zhang J, Xu H, Su H, Tan X, Tian D, Su M (2012) Clinical and immunopathological features of Moyamoya disease. PLoS One 7(4):e36386

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Li H, Zhang ZS, Dong ZN, Ma MJ, Yang WZ, Han C, du MM, Liu YX, Yang H, Liu W, Duan L, Cao WC (2011) Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case-control study. Stroke 42(4):1138–1139

    Article  CAS  PubMed  Google Scholar 

  55. Fujimura M, Fujimura T, Kakizaki A, Sato-Maeda M, Niizuma K, Tomata Y, Aiba S, Tominaga T (2018) Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease: involvement of intrinsic immune reaction in its pathogenesis. Brain Res 5(1679):39–44

    Article  CAS  Google Scholar 

  56. Ni G, Liu W, Huang X, Zhu S, Yue X, Chen Z, Chen M, Liu X, Xu G (2011) Increased levels of circulating SDF-1alpha and CD34+ CXCR4+ cells in patients with moyamoya disease. Eur J Neurol 18(11):1304–1309

    Article  CAS  PubMed  Google Scholar 

  57. Weng L, Cao X, Han L, Zhao H, Qiu S, Yan Y, Wang X, Chen X, Zheng W, Xu X, Gao Y, Chen Y, Li J, Yang Y, Xu Y (2017) Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci Rep 7(1):3071

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Kazumata K, Tha KK, Narita H, Kusumi I, Shichinohe H, Ito M, Nakayama N, Houkin K (2015) Chronic ischemia alters brain microstructural integrity and cognitive performance in adult moyamoya disease. Stroke 46(2):354–360

    Article  CAS  PubMed  Google Scholar 

  59. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis) (2012) Neurol Med Chir (Tokyo) 52(5):245–266

    Article  Google Scholar 

  60. Kim SK, Cho BK, Phi JH, Lee JY, Chae JH, Kim KJ, Hwang YS, Kim IO, Lee DS, Lee J, Wang KC (2010) Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 68(1):92–101

    Article  PubMed  Google Scholar 

  61. Guey S, Tournier-Lasserve E, Hervé D, Kossorotoff M (2015) Moyamoya disease and syndromes: from genetics to clinical management. Appl Clin Genet 8:49–68

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Lee JY, Choi YH, Cheon JE, Paeng JC, Ryu HW, Kim KJ, Phi JH, Wang KC, Cho BK, Chae JH, Kim SK (2014) Delayed posterior circulation insufficiency in pediatric moyamoya disease. J Neurol 261(12):2305–2313

    Article  PubMed  Google Scholar 

  63. Shi J, Meng R, Konakondla S, Ding Y, Duan Y, Wu D, Wang B, Luo Y, Ji X (2017) Cerebral watershed infarcts may be induced by hemodynamic changes in blood flow. Neurol Res 39(6):538–544

    Article  PubMed  Google Scholar 

  64. Zhao M, Deng X, Wang S et al (2017) Lacunar infarction in adult patients with moyamoya disease. Clin Neurol Neurosurg 164:81–86

    Article  PubMed  Google Scholar 

  65. Liu XJ, Zhang D, Wang S, Zhao YL, Teo M, Wang R, Cao Y, Ye X, Kang S, Zhao JZ (2015) Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China. J Neurosurg 122(2):392–399

    Article  PubMed  Google Scholar 

  66. Nah HW, Kwon SU, Kang DW, Ahn JS, Kwun BD, Kim JS (2012) Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different. Stroke 43(7):1947–1950

    Article  PubMed  Google Scholar 

  67. Ge P, Zhang Q, Ye X, Liu X, Deng X, Li H, Wang R, Zhang Y, Zhang D, Cao Y, Wang S, Zhao J (2017) Clinical features of hemorrhagic moyamoya disease in China. World Neurosurg. 106:224–230

    Article  PubMed  Google Scholar 

  68. Funaki T, Takahashi JC, Houkin K, Kuroda S, Takeuchi S, Fujimura M, Tomata Y, Miyamoto S, JAM Trial Investigators (2018) High rebleeding risk associated with choroidal collateral vessels in hemorrhagic moyamoya disease: analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. J Neurosurg:1–8

  69. Funaki T, Takahashi JC, Houkin K, Kuroda S, Takeuchi S, Fujimura M, Tomata Y, Miyamoto S, JAM Trial Investigators (2018) Angiographic features of hemorrhagic moyamoya disease with high recurrence risk: a supplementary analysis of the Japan adult Moyamoya trial. J Neurosurg 128(3):777–784

    Article  PubMed  Google Scholar 

  70. Kikuta K, Takagi Y, Nozaki K, Sawamoto N, Fukuyama H, Hashimoto N (2008) The presence of multiple microbleeds as a predictor of subsequent cerebral hemorrhage in patients with moyamoya disease. Neurosurgery 62(1):104–111

    Article  PubMed  Google Scholar 

  71. Kim JE, Jeon JS (2014) An update on the diagnosis and treatment of adult Moyamoya disease taking into consideration controversial issues. Neurol Res 36(5):407–416

    Article  PubMed  Google Scholar 

  72. Suzuki J, Kodama N (1971) Cerebrovascular “Moyamoya” disease. 2. Collateral routes to forebrain via ethmoid sinus and superior nasal meatus. Angiology 22(4):223–236

    Article  CAS  PubMed  Google Scholar 

  73. Kawano T, Ohmori Y, Kaku Y, Muta D, Uekawa K, Nakagawa T, Amadatsu T, Kasamo D, Shiraishi S, Kitajima M, Kuratsu JI (2016) Prolonged mean transit time detected by dynamic susceptibility contrast magnetic resonance imaging predicts cerebrovascular reserve impairment in patients with moyamoya disease. Cerebrovasc Dis 42(1–2):131–138

    Article  CAS  PubMed  Google Scholar 

  74. Qiao PG, Zuo ZW, Han C, Zhou J, Zhang HT, Duan L, Qian T, Li GJ (2017) Changes in hemodynamic response patterns in motor cortices measured by task-based functional magnetic resonance imaging in patients with moyamoya disease. J Comput Assist Tomogr 41(3):461–466

    Article  PubMed  Google Scholar 

  75. Kazumata K, Tha KK, Uchino H, Ito M, Nakayama N, Abumiya T (2017) Mapping altered brain connectivity and its clinical associations in adult moyamoya disease: a resting-state functional MRI study. PLoS One 12(8):e0182759

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Brinjikji W, Mossa-Basha M, Huston J, Rabinstein AA, Lanzino G, Lehman VT (2017) Intracranial vessel wall imaging for evaluation of steno-occlusive diseases and intracranial aneurysms. J Neuroradiol 44(2):123–134

    Article  PubMed  Google Scholar 

  77. Takagi Y, Hermanto Y, Takahashi JC, et al. (2016) Histopathological characteristics of distal middle cerebral artery in adult and pediatric patients with moyamoya disease. Neurol Med Chir (Tokyo) 15;56(6):345–349

  78. Kim YJ, Lee JK, Ahn SH, Kim BJ, Kang DW, Kim JS, Kwon SU (2016) Nonatheroscleotic isolated middle cerebral artery disease may be early manifestation of moyamoya disease. Stroke 47(9):2229–2235

    Article  PubMed  Google Scholar 

  79. Mossa-Basha M, de Havenon A, Becker KJ, Hallam DK, Levitt MR, Cohen WA, Hippe DS, Alexander MD, Tirschwell DL, Hatsukami T, Amlie-Lefond C, Yuan C (2016) Added value of vessel wall magnetic resonance imaging in the differentiation of moyamoya vasculopathies in a non-Asian cohort. Stroke 47(7):1782–1788

    Article  PubMed  PubMed Central  Google Scholar 

  80. Yu LB, He H, Zhao JZ, Wang R, Zhang Q, Shi ZY, Shao JS, Zhang D (2016) More precise imaging analysis and diagnosis of moyamoya disease and moyamoya syndrome using high-resolution magnetic resonance imaging. World Neurosurg. 96:252–260

    Article  PubMed  Google Scholar 

  81. Kim JM, Jung KH, Sohn CH, Park J, Moon J, Han MH, Roh JK (2013) High-resolution MR technique can distinguish moyamoya disease from atherosclerotic occlusion. Neurology 19;80(8):775–776

  82. Kim YJ, Lee DH, Kwon JY, Kang DW, Suh DC, Kim JS, Kwon SU (2013) High resolution MRI difference between moyamoya disease and intracranial atherosclerosis. Eur J Neurol 20(9):1311–1318

    Article  CAS  PubMed  Google Scholar 

  83. Yu LB, Zhang Q, Shi ZY, Wang MQ, Zhang D (2015) High-resolution magnetic resonance imaging of moyamoya disease. Chin Med J 128(23):3231–3237

    Article  PubMed  PubMed Central  Google Scholar 

  84. Oh BH, Moon HC, Baek HM, Lee YJ, Kim SW, Jeon YJ, Lee GS, Kim HR, Choi JH, Min KS, Lee MS, Kim YG, Kim DH, Kim WS, Park YS (2017) Comparison of 7T and 3T MRI in patients with moyamoya disease. Magn Reson Imaging 37:134–138

    Article  PubMed  Google Scholar 

  85. Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y (2005) Incidence and clinical features of disease progression in adult moyamoya disease. Stroke 36(10):2148–2153

    Article  PubMed  Google Scholar 

  86. Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, Nagata I, Toyoda K, Matsuda S, Suzuki A, Kataoka H, Nakamura F, Kamitani S, Nishimura A, Kurogi R, Sayama T, Iihara K, the J-ASPECT Study Collaborators (2016) Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open 6(3):e009942

    Article  PubMed  PubMed Central  Google Scholar 

  87. Smith ER, Scott RM (2005) Surgical management of moyamoya syndrome. Skull Base 15(1):15–26

    Article  PubMed  PubMed Central  Google Scholar 

  88. Kobayashi H, Hayashi M, Handa Y, Kabuto M, Noguchi Y, Aradachi H (1991) EC-IC bypass for adult patients with moyamoya disease. Neurol Res 13(2):113–116

    Article  CAS  PubMed  Google Scholar 

  89. Iwama T, Hashimoto N, Tsukahara T, Miyake H (1997) Superficial temporal artery to anterior cerebral artery direct anastomosis in patients with moyamoya disease. Clin Neurol Neurosurg 99(Suppl 2):S134–S136

    Article  PubMed  Google Scholar 

  90. Hayashi T, Shirane R, Tominaga T (2009) Additional surgery for postoperative ischemic symptoms in patients with moyamoya disease: the effectiveness of occipital artery-posterior cerebral artery bypass with an indirect procedure: technical case report. Neurosurgery 64(1):E195–E196

    Article  PubMed  Google Scholar 

  91. Matsushima Y, Inaba Y (1984) Moyamoya disease in children and its surgical treatment. Introduction of a new surgical procedure and its follow-up angiograms. Childs Brain 11(3):155–170

    CAS  PubMed  Google Scholar 

  92. Takeuchi S, Tsuchida T, Kobayashi K, Fukuda M, Ishii R, Tanaka R, Ito J (1983) Treatment of moyamoya disease by temporal muscle graft ‘encephalo-myo-synangiosis’. Childs Brain 10(1):1–15

    CAS  PubMed  Google Scholar 

  93. Bang JS, Kwon OK, Kim JE, Kang HS, Park H, Cho SY, Oh CW (2012) Quantitative angiographic comparison with the OSIRIS program between the direct and indirect revascularization modalities in adult moyamoya disease. Neurosurgery 70(3):625–632

    Article  PubMed  Google Scholar 

  94. Kawaguchi T, Fujita S, Hosoda K, Shose Y, Hamano S, Iwakura M, Tamaki N (1996) Multiple burr-hole operation for adult moyamoya disease. J Neurosurg 84(3):468–476

    Article  CAS  PubMed  Google Scholar 

  95. Noshiro S, Mikami T, Komatsu K, Kanno A, Enatsu R, Yazawa S, Nagamine T, Matsuhashi M, Mikuni N (2016) Neuromodulatory role of revascularization surgery in moyamoya disease. World Neurosurg. 91:473–482

    Article  PubMed  Google Scholar 

  96. Rashad S, M2 F, K1 N et al (2016) Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. Neurosurg Rev 39(4):615–623

  97. Gupta R, Moore M, J, Adeeb N et al (2016) Clinical presentation, progression, and treatment outcomes of moyamoya disease in the elderly. Acta Neurochir 158(12):2409–2414

  98. Zhang L, Xu K, Zhang Y, Wang X, Yu J (2015) Treatment strategies for aneurysms associated with moyamoya disease. Int J Med Sci 12(3):234–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Kuroda S, Kashiwazaki D, Hirata K, Shiga T, Houkin K, Tamaki N (2014) Effects of surgical revascularization on cerebral oxygen metabolism in patients with Moyamoya disease: an 15O-gas positron emission tomographic study. Stroke 45(9):2717–2721

    Article  CAS  PubMed  Google Scholar 

  100. Yamada S, Oki K, Itoh Y, Kuroda S, Houkin K, Tominaga T, Miyamoto S, Hashimoto N, Suzuki N, Research Committee on Spontaneous Occlusion of Circle of Willis (Moyamoya Disease) (2016) Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on moyamoya disease in Japan. J Stroke Cerebrovasc Dis 25(2):340–349

    Article  PubMed  Google Scholar 

  101. Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J, Takahashi JC, on behalf of the JAM Trial Investigators, Yamada K, Tomata Y, Fukui T, Fukuuchi Y, Ohmoto T, Kuwabara Y, Nagata I, Ono J, Machida T, Sakakibara R, Yamane K, Okita S, Iwama T, Kaku Y, Saito N, Fukuyama H, Houkin K, Kuroda S, Yabe I, Moriwaka F, Ogawa A, Ogasawara K, Yoshida K, Fujii K, Yamada M, Sato K, Akutsu T, Yamagata S, Takeuchi S, Hayashi K, Horie N, Yamada K, Osato T, Watanabe T, Honjo K, Sako K, Nakase H, Kawaguchi S, Nisimura F, Yamao J, Naritomi H, Inoue T, Abe H, Suzuki A, Ishikawa T, Akiyama Y, Suenaga T, Fujimura M, Nagahiro S, Uno M, Nishi K, Satomi J, Okada Y, Kawashima A, Yamaguchi K, Tsutsumi Y (2014) Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 45(5):1415–1421

    Article  PubMed  Google Scholar 

  102. Ren B, Zhang ZS, Liu WW, Bao XY, Li DS, Han C, Xian P, Zhao F, Wang H, Wang H, Duan L (2016) Surgical outcomes following encephaloduroarteriosynangio-sis in adult moyamoya disease associated with type 2 diabetes. J Neurosurg 125(2):308–314

    Article  PubMed  Google Scholar 

  103. Cheung AH, Lam AK, Ho WW et al (2017) Surgical outcome for moyamoya disease—clinical and perfusion computed tomography correlation. World Neurosurg. 98:81–88

    Article  PubMed  Google Scholar 

  104. Ge P, Ye X, Zhang Q, et al. Encephaloduroateriosynangiosis versus conservative treatment for patients with moyamoya disease at late Suzuki stage. J Clin Neurosci. 2018; pii: S0967–5868(17)31689–2

  105. Kazumata K, Ito M, Tokairin K, Ito Y, Houkin K, Nakayama N, Kuroda S, Ishikawa T, Kamiyama H (2014) The frequency of postoperative stroke in moyamoya disease following combined revascularization: a single-university series and systematic review. J Neurosurg 121(2):432–440

    Article  PubMed  Google Scholar 

  106. Cho WS, Kim JE, Kim CH, Ban SP, Kang HS, Son YJ, Bang JS, Sohn CH, Paeng JC, Oh CW (2014) Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke 45(10):3025–3031

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was sponsored by the National Key R&D Program (2017YFC1308401), the National Natural Science Foundation (81371289), and the Project of Beijing Municipal Top Talent of Healthy Work (2014-2-015) of China.

Author information

Author notes

  1. Shuling Shang and Da Zhou contributed equally to this work.

Authors and Affiliations

  1. Departments of Neurology, Radiology and Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China

    Shuling Shang, Da Zhou, Jingyuan Ya, Sijie Li, Qi Yang, Xunming Ji & Ran Meng

  2. Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100053, China

    Shuling Shang, Da Zhou, Jingyuan Ya, Sijie Li, Yuchuan Ding, Xunming Ji & Ran Meng

  3. Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Yuchuan Ding

  4. Department of Neurology, Xiehe Hospital, Tangshan, 063000, China

    Shuling Shang

Authors
  1. Shuling Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Da Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingyuan Ya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sijie Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuchuan Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xunming Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ran Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ran Meng.

Ethics declarations

This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent for this review was not required as per our Institutional Review Board.

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Highlights

• This manuscript extensively summarizes current advances in moyamoya disease, and encapsulates the clinical aspects including epidemiology, etiology, clinical findings, imaging diagnosis and treatment.

• Future development of moyamoya disease is briefly discussed as well.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shang, S., Zhou, D., Ya, J. et al. Progress in moyamoya disease. Neurosurg Rev 43, 371–382 (2020). https://doi.org/10.1007/s10143-018-0994-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10143-018-0994-5

Keywords

Search

Navigation